If they can get FDA approval by approx. mid 2022 that would be good.  That still leaves an approx. 1 year cushion before expiry of 2023 warrants for those that have them.  It also provides for a faster resolution that, if successful, would likely attract BP buyout interest in any case.

The alternative would have been to go with the BP 5 year plan and hope that fact alone would drive up the SP enough to cash out with a decent profit.  The problem I have with that BP plan is that any run up in the SP might be short lived before settling down in mediocre territory as the trial lumbers on.

So, I'm ok with their faster plan as above, and the COVID market potential of apabetalone might just be the additional sweetener to tickle the SP in the near term (to potentially take some profits) while waiting for BoM2 around mid to late 2022.